Posted by Michael Wonder on 26 Jan 2021
Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma
26 January 2021 - Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma
AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg) has been approved in China as an anti-inflammatory reliever to be taken as needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older.
